Pharma BD Deal Intelligence
A rare consumer-health M&A win: Reckitt's $2.3B acquisition of Adams Respiratory gave it Mucinex, still a top US OTC "Powerbrand" 17+ years later with new 2024 product launches and dedicated US manufacturing—no impairments or divestitures tied to the deal.
A rare consumer-health M&A success: Mucinex is still Reckitt's #1 US OTC brand and a global powerbrand 17+ years later, with continued product launches and new US manufacturing investment as recently as 2024.
Full analysis, sources & comparables →Reckitt offered $60/share cash (~$2.3B) for Adams; CEO Bart Becht called Mucinex 'a market and innovation leader in cough and congestion relief in the USA' and…
Adams stock climbed sharply on the buyout news; analysts viewed the $60/share price as a clean exit reflecting Mucinex's brand strength but noted Reckitt is…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
$60/share, ~$2.3B. Mucinex OTC respiratory franchise. Source: BioSpace, Drug Store News.
A rare consumer-health M&A success: Mucinex is still Reckitt's #1 US OTC brand and a global powerbrand 17+ years later, with continued product launches and new US manufacturing investment as recently as 2024.
Assessment window: 15yr post-close.
$332M Adams Respiratory Therapeutics FY2007 net sales (Mucinex/Delsym), USD
Acute cough and chest congestion are usually self-limited consequences of viral upper respiratory infection, post-nasal drip, or bronchitis. While most episodes resolve in 1-3 weeks, the symptom drives one of the largest OTC self-medication categories in the US, with consumers seeking expectorants (to thin and loosen mucus) and suppressants (to reduce cough frequency).
The US OTC cough/cold category in 2007 was dominated by Johnson & Johnson (Tylenol Cold, Sudafed PE), Pfizer Consumer (Robitussin, before its 2009 sale to GSK), Procter & Gamble (Vicks/NyQuil/DayQuil) and a long tail of private label. Adams Respiratory Therapeutics had carved out a defensible niche with Mucinex — the first FDA-approved (2002) extended-release guaifenesin under the agency's pre-1962 monograph reform — and Delsym, the leading 12-hour dextromethorphan suspension. Mucinex grew Adams' sales from $14M (FY03) to $332M (FY07), a 44% CAGR. Reckitt Benckiser's $2.3B/$60-per-share offer (a ~37% premium) was its first major US OTC healthcare entry, complementing its existing analgesic and stomach-care portfolio (Nurofen, Gaviscon — already Powerbrands in EU/AU but limited US presence). The deal repositioned Reckitt against P&G and J&J in US pharmacy aisles and gave Mucinex the global distribution muscle Adams lacked. Post-close, Mucinex became one of Reckitt's top-tier 'Powerbrands' globally.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Reckitt Benckiser plc / Adams Respiratory Therapeutics Inc. (this deal) | 2007 | $2.3B | 82 |
| Reckitt Benckiser plc / Boots Healthcare International | 2006 | $3.4B | 82 |
| Reckitt Benckiser plc / Boots Healthcare International | 2005 | $3.4B | 78 |
| Reckitt Benckiser plc / Schiff Nutrition International, Inc. | 2012 | $1.4B | 67 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Shire plc / New River Pharmaceuticals Inc. | 2007 | $2.6B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |